Breast Cancer Awareness Month

Adgero is a Proud Supporter of Breast Cancer Awareness

Click here to learn more about Adgero’s late stage development therapy for the treatment of cutaneous metastatic breast cancer (CMBC).

Control Prev
Control Prev

Developing Late Stage Photodynamic Therapy Platform for the Treatment of Serious Oncology Indications

Late-Stage Development Product for Cutaneous Metastatic Breast Cancer (CMBC)

How REM-001 Therapy Works CEO Webcast

Pipeline

Our REM-001 Therapy provided high response rates in treating CMBC tumors in multiple Phase 2 and 3 clinical trials

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
REM-001 Cutaneous Metastatic Breast Cancer
Preclinical
Phase 1
Phase 2
Phase 3
Market
REM-001 Recurrent Basal Cell Carcinoma with Nevus Syndrome (BCNS) and Locally Advanced Basal Cell Carcinoma (laBCC)
Preclinical
Phase 1
Phase 2
Phase 3
Market
REM-001 Cutaneous Metastatic Cancers Other than CMBC (e.g., Lung, Ovarian and Colon)
Preclinical
Phase 1
Phase 2
Phase 3
Market

Inducing Tumor Cell Death

Photodynamic therapy (PDT) uses photosensitizers that, when exposed to light, act as a catalyst to produce a form of oxygen that induces local tumor cell death.

Our PDT Technology

Developing Novel Therapies to Treat Cancer

We are focused on leveraging our proprietary photodynamic therapy (PDT) platform to build a robust pipeline of products for the treatment of serious oncology indications.

About Adgero

Experienced Management Team

Our strong management team and scientific advisory board boast extensive backgrounds in oncology and photodynamic therapy.

Meet Our Team

Corporate Presentation

View our latest corporate presentation

View investor presentation